Genezen reports that the company became the first CDMO to license CSL’s Cytegrity™ cell line production system that was designed for the production of lentiviral vectors (LVVs).

“We have significant, hands-on experience scaling up and producing LVV using this stable production system at our GMP vector facility in Fishers, IN,” said Steve Favaloro, president and CEO of Genezen. “Stable producer cell lines can be developed for clients in under four months, and this system will help alleviate the current global viral vector shortage by providing customers with a scalable, high quality vector platform.”

“Leveraging our experience and expertise with Cytegrity, I believe that Genezen can truly help customers get to the clinic faster and produce higher quality LVV at scale in the long run,” added Pratima Cherukuri, CSO of Genezen.

“Following many years of investment in the development of the cell line at CSL in collaboration with our partners, the Cytegrity cell line will potentially lower cost of goods and enable quicker scaleup to clinical and commercial manufacture which, in turn, will benefit patients in gaining access to therapies faster,” according to Vicky Pirzas, SVP, biopharmaceutical product development, CSL.

Previous articleDNA Melting Curves Could Speed Blood-Borne Pathogen Detection
Next articleStockWatch: Nvidia Shares Leap Again after Reporting Record Revenues